Idexx Laboratories INC /DE

IDEXX Laboratories announced robust second quarter results, exceeding expectations with significant revenue growth and increased earnings per share, leading to an upward revision of its full-year financial guidance.

IDEXX Laboratories shareholders approved amendments to declassify the Board and grant shareholders the right to call special meetings.

IDEXX Laboratories announced first quarter 2026 results with 14% reported revenue growth and raised full-year guidance, driven by strong performance in its Companion Animal Group.

IDEXX Laboratories announces the mutual agreement for Executive Vice President Nimrata Hunt, PhD, to depart, with a comprehensive separation package totaling $2.29 million.

IDEXX Laboratories announced strong fourth quarter and full year 2025 financial results, driven by pet healthcare innovation and commercial execution, and provided an optimistic 2026 outlook.

IDEXX Laboratories, Inc. announced Michael Erickson, PhD, will become President and CEO on May 12, 2026, succeeding Jonathan Mazelsky, who will transition to Executive Chair before retiring in May 2027.

IDEXX Laboratories announced a robust first quarter for 2026, with significant revenue growth driven by its Companion Animal Group and improved profitability.

IDEXX Laboratories reports robust third-quarter 2025 financial results, driven by significant growth in companion animal diagnostics and improved profitability.

IDEXX Laboratories reports robust Q2 2025 financial results with significant revenue and earnings per share growth, driven by strong performance in its Companion Animal Group.

IDEXX Laboratories' Q1 2025 results show revenue and earnings growth, primarily driven by the Companion Animal Group, with a focus on recurring diagnostic revenue.

IDEXX Laboratories reports a 6.1% organic revenue growth in Q3, driven by strong performance in its Companion Animal Group, while managing macroeconomic challenges.

IDEXX Laboratories' second-quarter results show revenue growth offset by a significant litigation expense, impacting overall profitability.

IDEXX Laboratories' 2024 10-K filing reveals a year of growth driven by companion animal diagnostics and strategic initiatives, while navigating competitive pressures and regulatory complexities.

IDEXX Laboratories' 2023 annual report highlights growth in companion animal diagnostics and strategic investments, while navigating supply chain and economic challenges.

Joseph L Hooley, a Director of Idexx Laboratories Inc /De, received 49 shares of common stock on July 30, 2026.

George Fennell, Executive Vice President at IDEXX Laboratories, reported transactions involving restricted stock units and common stock.

IDEXX Laboratories Director Sophie V. Vandebroek was granted stock options and restricted stock units on May 12, 2026.

Sam Samad, a Director at IDEXX LABORATORIES INC /DE, was granted stock options and deferred stock units on May 12, 2026.

Director Karen Peacock acquired stock options and deferred stock units in IDEXX LABORATORIES INC.

IDEXX Laboratories Director Lawrence D. Kingsley was granted stock options and restricted stock units on May 12, 2026, as detailed in a Form 4 filing.

IDEXX Laboratories achieved solid 2025 financial results with 10% revenue growth and 23% diluted EPS increase, alongside a planned CEO transition and significant innovation advancements.

IDEXX Laboratories has filed a definitive proxy statement with the SEC.

IDEXX Laboratories reports strong financial results and advancements in its innovation-driven growth strategy, positioning the company for sustained long-term value creation.

IDEXX Laboratories has filed a definitive proxy statement with the SEC.

IDEXX Laboratories has released its proxy statement detailing proposals for the upcoming annual shareholder meeting on May 6, 2024, including the election of directors, ratification of the accounting firm, and an advisory vote on executive compensation.

Vanguard Capital Management has reported a beneficial ownership of 7.51% in IDEXX Laboratories Inc., holding over 5.97 million shares.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in IDEXX Laboratories Inc. following an internal realignment.

BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, disclosing a 9.4% beneficial ownership stake in IDEXX Laboratories Inc. as of March 31, 2025.